Group 1 - The company Hunan Fangsheng Pharmaceutical Co., Ltd. has acquired the ownership of 20 registered drug varieties from Kangyi Pharmaceutical Co., Ltd. in Hong Kong [1] - A joint venture company in Hong Kong is to be established with a registered capital of 20 million HKD, where the company will hold 35% initially [1] - The company plans to sign a new drug transfer agreement with Kangyi Pharmaceutical after the establishment of the joint venture [1] Group 2 - Due to regulatory issues regarding foreign investment, the company has adjusted its shareholding structure in the joint venture, increasing its stake from 35% to 50% and raising its investment from 7 million HKD to 10 million HKD [2] - The new shareholding structure includes other parties with varying stakes, ensuring compliance with investment regulations [2][3] - The joint venture will officially sign the investment cooperation agreement to clarify the rights and obligations of all parties involved [3] Group 3 - The adjustment in the shareholding structure of the joint venture is not expected to significantly impact the company's normal operations or financial results [3] - The transfer of drug licenses is still in process and is not affected by the changes in the joint venture [3]